| 沈维敏,许佳毅,唐 曦,范志强,葛晓晓.培美曲塞化疗对非小细胞肺癌患者T淋巴细胞亚群的影响[J].,2019,19(19):3644-3647 |
| 培美曲塞化疗对非小细胞肺癌患者T淋巴细胞亚群的影响 |
| Changes of T Lymphocyte Subsets before and after Pemetrexed Chemotherapy in Patients with Non-small Cell Lung Cancer |
| 投稿时间：2019-03-23 修订日期：2019-04-18 |
| DOI：10.13241/j.cnki.pmb.2019.19.010 |
| 中文关键词: 培美曲塞 化疗 非小细胞肺癌 T淋巴细胞 |
| 英文关键词: Pemetrexed Chemotherapy Non-small cell lung cancer T lymphocytes |
| 基金项目:上海市卫计委科研基金项目(20184Y0335) |
|
| 摘要点击次数: 1013 |
| 全文下载次数: 733 |
| 中文摘要: |
| 摘要 目的：探究培美曲塞化疗对非小细胞肺癌患者T淋巴细胞亚群的影响，评价其临床应用价值。方法：选取2016年3月到2017年3月我院肿瘤内科收治的100例非小细胞肺癌患者进行研究，其中，50例非小细胞肺癌患者采用培美曲塞化疗、50例采用多西他赛进行化疗。比较患者治疗前后T淋巴细胞亚群变化情况。结果：与化疗前比较，非小细胞肺癌患者化疗后CD3+、CD4+、CD4+/CD8+比值以及NK细胞显著上升，而CD8+显著下降(P<0.05)。为了验证培美曲塞对非小细胞肺癌患者的安全性，本研究将部分患者采用多西他赛化疗，非小细胞肺癌患者培美曲塞和多西他赛化疗后CD3+、CD4+、CD4+/CD8+比值以及NK细胞相比差异不大(P>0.05)。此外，两组不良反应如恶心、呕吐，细胞减少，血小板减少，肾功能障碍差异不大(P>0.05)。结论：培美曲塞化疗可以显著改变非小细胞患者的T淋巴细胞亚群构成，提高患者免疫功能和治疗效果。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of pemetrexed chemotherapy on T lymphocyte subsets in patients with non-small cell lung cancer, and to evaluate its clinical application value. Methods: From March 2016 to March 2017, 100 patients with NSCLC admitted to the department of oncology of our hospital were selected for study. Among them, 50 patients with NSCLC received chemotherapy with pemetrexed and 50 patients received chemotherapy with docetaxel. The T lymphocyte subsets were compared before and after treatment. Results: Compared with before chemotherapy, CD3+, CD4+, CD4+/CD8+ ratio and NK cells significantly increased after chemotherapy in patients with non-small cell lung cancer, while CD8+ significantly decreased (P<0.05). In order to verify the safety of pemetrexed in patients with non-small cell lung cancer, some patients were treated with docetaxel chemotherapy in this study, and the differences in CD3+, CD4+, CD4+/CD8+ ratio and NK cells between pemetrexed and docetaxel after chemotherapy were not significant (P>0.05). In addition, adverse reactions such as nausea and vomiting, cytopenia, thrombocytopenia and renal dysfunction were not significantly different between the two groups (P>0.05). Conclusion: Chemotherapeutic treatment with pemetrexate can significantly change the composition of T lymphocyte subsets in non-small cell patients, and improve the immune function and therapeutic effect of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
